SCHEMBL3216764

SCHEMBL3216764

O=S(=O)(c1ccccc1Cl)N1CCN(c2ccccc2F)CC1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.64
LMNA P02545 6/20 0.64
SMN1; SMN2 Q16637 4/20 0.64
HSD17B10 Q99714 2/20 0.64
TSHR P16473 2/20 0.64
TP53 P04637 1/20 0.64
POLB P06746 4/20 0.60
PKM P14618 1/20 0.60
MAPK1 P28482 1/20 0.60
HSD11B1 P28845 1/20 0.60
USP2 O75604 1/20 0.59
HTT P42858 2/20 0.59
CHRM4 P08173 2/20 0.56
MAPT P10636 1/20 0.56
KDM4E B2RXH2 1/20 0.55
GLA P06280 1/20 0.55
KMT2A Q03164 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2961026 0.89 CHRM4 (0.62) ALDH1A1LMNASMN1; SMN2HSD17B10TSHR
SCHEMBL3221923 0.86 ALDH1A1 (0.52) ALDH1A1LMNASMN1; SMN2HSD17B10TSHR
SCHEMBL5331434 0.84 CHRM4 (0.64) ALDH1A1LMNASMN1; SMN2TSHRPKM
SCHEMBL3223609 0.84 CHRM4 (0.57) LMNATSHRHSD11B1CHRM4MAPT
SCHEMBL2963243 0.82 CHRM4 (0.56) ALDH1A1LMNASMN1; SMN2HSD17B10TSHR
SCHEMBL2961967 0.82 ALDH1A1 (0.61) ALDH1A1LMNASMN1; SMN2PKMMAPK1
SCHEMBL10723724 0.82 CHRM4 (0.64) ALDH1A1LMNASMN1; SMN2TSHRPOLB
SCHEMBL3212651 0.82 HSD11B1 (0.67) ALDH1A1SMN1; SMN2HSD11B1CHRM4KMT2A
SCHEMBL3207442 0.79 LMNA (0.74) ALDH1A1LMNASMN1; SMN2HSD17B10TSHR
SCHEMBL2959432 0.79 CHRM4 (0.52) ALDH1A1LMNASMN1; SMN2HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029648-A1 11-Beta HSD1 Inhibitors XIANG JASON SHAOYUN 2010-02-04 US disclosed
US-7632838-B2 11-beta HSD1 inhibitors WYETH (US) 2009-12-15 US disclosed
EP-1981848-A2 11-BETA HSD1 INHIBITORS Wyeth (US) 2008-10-22 EP disclosed
US-20070219198-A1 11-Beta HSD 1 inhibitors WYETH (US) 2007-09-20 US disclosed
WO-2007092435-A2 11-BETA HSD1 INHIBITORS WYETH (US) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029648-A1 11-Beta HSD1 Inhibitors HSD11B1, HSD3B1, HSD11B2 ALDH1A1 116/4885LMNA 3748/4885SMN1; SMN2 3575/4885
US-20070219198-A1 11-Beta HSD 1 inhibitors HSD11B1, HSD11B2, HSD3B1 ALDH1A1 123/4885LMNA 3681/4885SMN1; SMN2 3686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.